Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.69 |
| ▸ | SRC | P12931 | 9/20 | 0.69 |
| ▸ | LCK | P06239 | 5/20 | 0.69 |
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | FYN | P06241 | 3/20 | 0.69 |
| ▸ | YES1 | P07947 | 3/20 | 0.69 |
| ▸ | LYN | P07948 | 3/20 | 0.69 |
| ▸ | HCK | P08631 | 3/20 | 0.69 |
| ▸ | KIT | P10721 | 3/20 | 0.69 |
| ▸ | BCR | P11274 | 3/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.69 |
| ▸ | CSF1R | P07333 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | BRAF | P15056 | 2/20 | 0.69 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.69 |
| ▸ | EPHA3 | P29320 | 2/20 | 0.69 |
| ▸ | EPHA8 | P29322 | 2/20 | 0.69 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30428970 | 0.89 | HDAC3 (0.84) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL25208403 | 0.89 | HDAC3 (0.84) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL30430113 | 0.89 | HDAC3 (0.85) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL25232237 | 0.89 | HDAC3 (0.85) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL1147171 | 0.88 | HDAC3 (0.84) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL16907546 | 0.87 | ABL1 (0.80) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL4293505 | 0.87 | ABL1 (0.79) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL30715234 | 0.87 | ABL1 (0.79) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL13626293 | 0.86 | ABL1 (0.89) | ABL1SRCLCKEGFRFYN | |
| SCHEMBL24535376 | 0.86 | ABL1 (0.78) | ABL1SRCLCKEGFRFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169244-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140128410-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8426419-B2 | Tyrosine kinase inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20110178095-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2011-07-21 | — | — | US | disclosed |
| US-7888361-B2 | anticancer; inhibits both BCR-ABL and histone deacetylase activity; N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-(hydroxyamino)-2-oxoethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide | CURIS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| EP-2061468-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| US-20080125440-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033746-A2 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | ABL1 1691/4885SRC 901/4885LCK 969/4885 |
| US-20110178095-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | ABL1 2/4885SRC 3/4885LCK 1/4885 |
| US-20140128410-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | ABL1 2/4885SRC 3/4885LCK 1/4885 |
| US-20080125440-A1 | TYROSINE KINASE INHIBITORS CONTAINING A ZINC BINDING MOIETY | LCK, ABL1, SRC | ABL1 2/4885SRC 3/4885LCK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.